SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:28e2f84f-c58d-4926-9707-c5d230b4bd31"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:28e2f84f-c58d-4926-9707-c5d230b4bd31" > Impact of pre-biolo...

  • Perez-de-Llano, LuisUniversity Hospital Lucus Augusti (författare)

Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

  • Artikel/kapitelEngelska

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:28e2f84f-c58d-4926-9707-c5d230b4bd31
  • https://lup.lub.lu.se/record/28e2f84f-c58d-4926-9707-c5d230b4bd31URI
  • https://doi.org/10.1016/j.anai.2023.12.023DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Background: There is little agreement on clinically useful criteria for identifying real-world responders to biologic treatments for asthma. Objective: To investigate the impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in adults with severe asthma. Methods: This was a longitudinal, cohort study across 22 countries participating in the International Severe Asthma Registry (https://isaregistries.org/) between May 2017 and January 2023. Change in 4 asthma domains (exacerbation rate, asthma control, long-term oral corticosteroid [LTOCS] dose, and lung function) was assessed from biologic initiation to 1 year post-treatment (minimum 24 weeks). Pre- to post-biologic changes for responders and nonresponders were described along a categorical gradient for each domain derived from pre-biologic distributions (exacerbation rate: 0 to 6+/y; asthma control: well controlled to uncontrolled; LTOCS: 0 to >30 mg/d; percent-predicted forced expiratory volume in 1 second [ppFEV1]: <50% to ≥80%). Results: Percentage of biologic responders (ie, those with a category improvement pre- to post-biologic) varied by domain and increased with greater pre-biologic impairment, increasing from 70.2% to 90.0% for exacerbation rate, 46.3% to 52.3% for asthma control, 31.1% to 58.5% for LTOCS daily dose, and 35.8% to 50.6% for ppFEV1. The proportion of patients having improvement post-biologic tended to be greater for anti–IL-5/5R compared with for anti-IgE for exacerbation, asthma control, and ppFEV1 domains, irrespective of pre-biologic impairment. Conclusion: Our results provide realistic outcome-specific post-biologic expectations for both physicians and patients, will be foundational to inform future work on a multidimensional approach to define and assess biologic responders and response, and may enhance appropriate patient selection for biologic therapies. Trial Registration: The ISAR database has ethical approval from the Anonymous Data Ethics Protocols and Transparency (ADEPT) committee (ADEPT0218) and is registered with the European Union Electronic Register of Post-Authorization studies (ENCEPP/DSPP/23720). The study was designed, implemented, and reported in compliance with the European Network Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP) Code of Conduct (EUPAS38288) and with all applicable local and international laws and regulation, and registered with ENCEPP (https://www.encepp.eu/encepp/viewResource.htm?id=38289). Governance was provided by ADEPT (registration number: ADEPT1220).

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Scelo, GhislaineObservational and Pragmatic Research Institute Pte Ltd (författare)
  • Canonica, G. WalterHumanitas Research Hospital,Humanitas University (författare)
  • Chen, WenjiaNational University of Singapore (författare)
  • Henley, WilliamUniversity of Exeter,Observational and Pragmatic Research Institute Pte Ltd (författare)
  • Larenas-Linnemann, Désirée (författare)
  • Peters, Matthew J.Macquarie University, Sydney,Concord Repatriation General Hospital (författare)
  • Pfeffer, Paul E.Barts Health NHS Trust,Queen Mary University (författare)
  • Tran, Trung N.AstraZeneca, UK (författare)
  • Ulrik, Charlotte SuppliHvidovre Hospital (författare)
  • Popov, Todor A.University Hospital St. Ivan Rilski (författare)
  • Sadatsafavi, MohsenUniversity of British Columbia (författare)
  • Hew, MarkMonash University (författare)
  • Máspero, JorgeUniversity of Buenos Aires (författare)
  • Gibson, Peter G.Hunter Medical Research Institute, Australia,University of Newcastle (författare)
  • Christoff, George C.Medical University of Sofia (författare)
  • Fitzgerald, J. MarkUniversity of British Columbia (författare)
  • Torres-Duque, Carlos A.University Of La Sabana (författare)
  • Porsbjerg, Celeste M.Bispebjerg Hospital (författare)
  • Papadopoulos, Nikolaos GNational and Kapodistrian University of Athens,University of Manchester (författare)
  • Papaioannou, Andriana I.National and Kapodistrian University of Athens (författare)
  • Heffler, EnricoHumanitas University,Humanitas Research Hospital (författare)
  • Iwanaga, Takashi (författare)
  • Al-Ahmad, MonaKuwait University (författare)
  • Kuna, PiotrMedical University of Lodz (författare)
  • Fonseca, João A.University of Porto (författare)
  • Al-Lehebi, RiyadAlfaisal University (författare)
  • Rhee, Chin Kook (författare)
  • Koh, Mariko SiyueSingapore General Hospital (författare)
  • Cosio, Borja G.Hospital Universitario Son Espases (författare)
  • Perng (Steve), Diahn WarngTaipei Veterans General Hospital,National Yang-Ming University Taiwan (författare)
  • Mahboub, Bassam (författare)
  • Menzies-Gow, Andrew N.Royal Brompton and Harefield NHS Foundation Trust,AstraZeneca, UK (författare)
  • Jackson, David J.Guy's Hospital (författare)
  • Busby, John (författare)
  • Heaney, Liam G.Queen's University Belfast (författare)
  • Patel, Pujan H.Royal Brompton Hospital (författare)
  • Wang, EileenUniversity of Colorado School of Medicine (författare)
  • Wechsler, Michael E.National Jewish Health (författare)
  • Altraja, AlanUniversity of Tartu (författare)
  • Lehtimäki, LauriUniversity of Tampere,Tampere University Hospital (författare)
  • Bourdin, Arnaud (författare)
  • Bjermer, LeifLund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Klinisk lungmedicin,Forskargrupper vid Lunds universitet,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Clinical Respiratory Medicine,Lund University Research Groups,Skåne University Hospital(Swepub:lu)lung-lbj (författare)
  • Bulathsinhala, LakminiObservational and Pragmatic Research Institute Pte Ltd (författare)
  • Carter, VictoriaObservational and Pragmatic Research Institute Pte Ltd (författare)
  • Murray, Ruth (författare)
  • Beastall, AaronObservational and Pragmatic Research Institute Pte Ltd (författare)
  • Denton, EveMonash University (författare)
  • Price, David B.University of Aberdeen,Observational and Pragmatic Research Institute Pte Ltd (författare)
  • University Hospital Lucus AugustiObservational and Pragmatic Research Institute Pte Ltd (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Annals of Allergy, Asthma and Immunology1081-1206

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy